(ECOR) Electrocore - Ratings and Ratios
Non-invasive, Vagus Nerve, Stimulation, Devices
ECOR EPS (Earnings per Share)
ECOR Revenue
Description: ECOR Electrocore
ElectroCore, Inc. is a pioneering bioelectronic medicine company that has developed a proprietary non-invasive vagus nerve stimulation (nVNS) technology platform. This innovative technology has far-reaching implications for the treatment of various medical conditions, including migraine, episodic cluster headache, and other chronic pain and wellness disorders. The companys flagship product, gammaCore, is a prescription-only handheld device designed for regular or intermittent use to alleviate pain associated with these conditions.
The companys product portfolio is diverse and expanding, with offerings such as Truvaga350, a consumer electronics general wellness product, and Truvaga Plus, an app-enabled general wellness product. Additionally, electroCore is exploring the application of its nVNS technology in human performance enhancement with TAC-STIM and treating primary headache conditions with gammaCore Sapphire, a portable, reusable, and rechargeable prescription medical device.
From a technical analysis perspective, ECORs stock has been trending downward, with its current price of $5.31 being significantly lower than its 52-week high of $19.37. The stocks short-term and long-term moving averages (SMA20: $6.18, SMA50: $6.79, SMA200: $10.31) indicate a bearish trend. The Average True Range (ATR) of 0.74, representing 13.95% of the current price, suggests relatively high volatility.
Considering the fundamental data, electroCores market capitalization stands at $40.07M USD, with no reported P/E ratio due to negative earnings. The Return on Equity (RoE) is -149.04, indicating significant losses. However, the companys innovative technology and expanding product portfolio could potentially drive future growth.
Based on the technical and fundamental data, a forecast for ECORs stock price could be derived. Given the current bearish trend and high volatility, a potential support level could be around $4.61 (52-week low). If the company can successfully commercialize its products and improve its financial performance, a potential resistance level could be around $10-$12, driven by the SMA200. A more optimistic scenario, driven by significant growth in revenue and earnings, could see the stock price potentially reaching $15-$20 in the long term. However, this is contingent upon the companys ability to overcome its current financial challenges and achieve profitability.
ECOR Stock Overview
| Market Cap in USD | 39m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2018-06-22 |
ECOR Stock Ratings
| Growth Rating | -59.8% |
| Fundamental | 38.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.4% |
| Analyst Rating | 4.60 of 5 |
ECOR Dividends
Currently no dividends paidECOR Growth Ratios
| Growth Correlation 3m | -36.1% |
| Growth Correlation 12m | -59.3% |
| Growth Correlation 5y | -54.1% |
| CAGR 5y | -15.01% |
| CAGR/Max DD 3y | -0.19 |
| CAGR/Mean DD 3y | -0.57 |
| Sharpe Ratio 12m | 0.12 |
| Alpha | -40.18 |
| Beta | 0.876 |
| Volatility | 81.74% |
| Current Volume | 31.6k |
| Average Volume 20d | 58.7k |
| Stop Loss | 4.4 (-7.2%) |
| Signal | -1.42 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-13.3m TTM) > 0 and > 6% of Revenue (6% = 1.66m TTM) |
| FCFTA -0.48 (>2.0%) and ΔFCFTA 18.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.39% (prev 50.31%; Δ -46.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.52 (>3.0%) and CFO -7.60m > Net Income -13.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (8.32m) change vs 12m ago 18.02% (target <= -2.0% for YES) |
| Gross Margin 85.52% (prev 83.61%; Δ 1.91pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 150.1% (prev 95.20%; Δ 54.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -59.18
| (A) 0.06 = (Total Current Assets 10.6m - Total Current Liabilities 9.62m) / Total Assets 14.6m |
| (B) -12.68 = Retained Earnings (Balance) -184.6m / Total Assets 14.6m |
| warn (B) unusual magnitude: -12.68 — check mapping/units |
| (C) -0.57 = EBIT TTM -10.6m / Avg Total Assets 18.5m |
| (D) -13.73 = Book Value of Equity -184.6m / Total Liabilities 13.4m |
| Total Rating: -59.18 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.18
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield -19.50% = -5.0 |
| 3. FCF Margin -25.08% = -7.50 |
| 4. Debt/Equity 3.80 = -1.83 |
| 5. Debt/Ebitda -0.44 = -2.50 |
| 7. RoE -235.8% = -2.50 |
| 8. Rev. Trend 95.54% = 4.78 |
| 9. Rev. CAGR 61.48% = 2.50 |
| 10. EPS Trend 89.10% = 2.23 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ECOR shares?
Over the past week, the price has changed by -3.66%, over one month by -9.54%, over three months by -9.20% and over the past year by -23.55%.
Is Electrocore a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ECOR is around 3.86 USD . This means that ECOR is currently overvalued and has a potential downside of -18.57%.
Is ECOR a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ECOR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.4 | 351.5% |
| Analysts Target Price | 21.4 | 351.5% |
| ValueRay Target Price | 4.3 | -9.3% |
Last update: 2025-09-05 04:40
ECOR Fundamental Data Overview
CCE Cash And Equivalents = 7.39m USD (Cash And Short Term Investments, last quarter)
P/S = 1.4003
P/B = 35.8391
Beta = 0.271
Revenue TTM = 27.7m USD
EBIT TTM = -10.6m USD
EBITDA TTM = -9.63m USD
Long Term Debt = 3.83m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 405.0k USD (from shortTermDebt, last quarter)
Debt = 4.23m USD (Calculated: Short Term 405.0k + Long Term 3.83m)
Net Debt = 610.0k USD (from netDebt column, last quarter)
Enterprise Value = 35.6m USD (38.8m + Debt 4.23m - CCE 7.39m)
Interest Coverage Ratio = unknown (Ebit TTM -10.6m / Interest Expense TTM 0.0)
FCF Yield = -19.50% (FCF TTM -6.95m / Enterprise Value 35.6m)
FCF Margin = -25.08% (FCF TTM -6.95m / Revenue TTM 27.7m)
Net Margin = -47.84% (Net Income TTM -13.3m / Revenue TTM 27.7m)
Gross Margin = 85.52% ((Revenue TTM 27.7m - Cost of Revenue TTM 4.01m) / Revenue TTM)
Tobins Q-Ratio = -0.19 (set to none) (Enterprise Value 35.6m / Book Value Of Equity -184.6m)
Interest Expense / Debt = 2.81% (Interest Expense 119.0k / Debt 4.23m)
Taxrate = 21.0% (US default)
NOPAT = -10.6m (EBIT -10.6m, no tax applied on loss)
Current Ratio = 1.10 (Total Current Assets 10.6m / Total Current Liabilities 9.62m)
Debt / Equity = 3.80 (Debt 4.23m / last Quarter total Stockholder Equity 1.11m)
Debt / EBITDA = -0.44 (Net Debt 610.0k / EBITDA -9.63m)
Debt / FCF = -0.61 (Debt 4.23m / FCF TTM -6.95m)
Total Stockholder Equity = 5.62m (last 4 quarters mean)
RoA = -91.02% (Net Income -13.3m, Total Assets 14.6m )
RoE = -235.8% (Net Income TTM -13.3m / Total Stockholder Equity 5.62m)
RoCE = -111.8% (set to none) (Ebit -10.6m / (Equity 5.62m + L.T.Debt 3.83m))
RoIC = -188.0% (set to none) (NOPAT -10.6m / Invested Capital 5.62m)
WACC = 8.55% (E(38.8m)/V(43.0m) * Re(9.24%)) + (D(4.23m)/V(43.0m) * Rd(2.81%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 5.24%
Discount Rate = 9.24% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -6.95m)
Revenue Correlation: 95.54 | Revenue CAGR: 61.48%
Rev Growth-of-Growth: -36.78
EPS Correlation: 89.10 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -42.10
Additional Sources for ECOR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle